Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce R Schackman

Showing results (91-100 of 222) with videos related to

Pageof 23
Sort By:
Pharmacoeconomics|June 22, 2019
Structural Design and Data Requirements for Simulation Modelling in HIV/AIDS: A Narrative ReviewXiao Zang, Emanuel Krebs, Linwei Wang, et al.
Journal of Crohn'S & Colitis|May 10, 2018
The Impact of Opioid Epidemic Trends on Hospitalised Inflammatory Bowel Disease PatientsShirley Cohen-Mekelburg, Russell Rosenblatt, Stephanie Gold, et al.
The International Journal on Drug Policy|June 9, 2015
An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potentialDavid C Perlman, Ashly E Jordan, Anneli Uuskula, et al.
Addiction Science & Clinical Practice|October 2, 2025
Cost of implementing evidence-based practices to reduce opioid overdose fatalities in New York State communitiesJazmine M Li, Dawn Gruss, Timothy Hunt, et al.
Substance Abuse|October 20, 2021
Costs of opioid overdose education and naloxone distribution in New York CityCzarina N Behrends, Sarah Gutkind, Emily Winkelstein, et al.
Annals of Internal Medicine|December 6, 2006
Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costsA David Paltiel, Rochelle P Walensky, Bruce R Schackman, et al.
Health Affairs (Project Hope)|August 7, 2013
A call for evidence-based medical treatment of opioid dependence in the United States and CanadaBohdan Nosyk, M Douglas Anglin, Suzanne Brissette, et al.
The Journal of Infectious Diseases|April 19, 2008
Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell countsHeather J Ribaudo, Daniel R Kuritzkes, Christina M Lalama, et al.
HIV Clinical Trials|February 7, 2012
Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug developmentBethany L Morris, Callie A Scott, Timothy J Wilkin, et al.
Journal of General Internal Medicine|September 13, 2018
First Opioid Prescription and Subsequent High-Risk Opioid Use: a National Study of Privately Insured and Medicare Advantage AdultsYongkang Zhang, Phyllis Johnson, Philip J Jeng, et al.
Pageof 23

Showing results (91-100 of 222) with videos related to

Sort By:
Pageof 23
Pharmacoeconomics|June 22, 2019
Structural Design and Data Requirements for Simulation Modelling in HIV/AIDS: A Narrative ReviewXiao Zang, Emanuel Krebs, Linwei Wang, et al.
Journal of Crohn'S & Colitis|May 10, 2018
The Impact of Opioid Epidemic Trends on Hospitalised Inflammatory Bowel Disease PatientsShirley Cohen-Mekelburg, Russell Rosenblatt, Stephanie Gold, et al.
The International Journal on Drug Policy|June 9, 2015
An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potentialDavid C Perlman, Ashly E Jordan, Anneli Uuskula, et al.
Addiction Science & Clinical Practice|October 2, 2025
Cost of implementing evidence-based practices to reduce opioid overdose fatalities in New York State communitiesJazmine M Li, Dawn Gruss, Timothy Hunt, et al.
Substance Abuse|October 20, 2021
Costs of opioid overdose education and naloxone distribution in New York CityCzarina N Behrends, Sarah Gutkind, Emily Winkelstein, et al.
Annals of Internal Medicine|December 6, 2006
Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costsA David Paltiel, Rochelle P Walensky, Bruce R Schackman, et al.
Health Affairs (Project Hope)|August 7, 2013
A call for evidence-based medical treatment of opioid dependence in the United States and CanadaBohdan Nosyk, M Douglas Anglin, Suzanne Brissette, et al.
The Journal of Infectious Diseases|April 19, 2008
Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell countsHeather J Ribaudo, Daniel R Kuritzkes, Christina M Lalama, et al.
HIV Clinical Trials|February 7, 2012
Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug developmentBethany L Morris, Callie A Scott, Timothy J Wilkin, et al.
Journal of General Internal Medicine|September 13, 2018
First Opioid Prescription and Subsequent High-Risk Opioid Use: a National Study of Privately Insured and Medicare Advantage AdultsYongkang Zhang, Phyllis Johnson, Philip J Jeng, et al.
Pageof 23